Brett King

1 month ago | hcplive.com | Tim Smith |Brett King

At the American Academy of Dermatology (AAD) Conference in Orlando, the HCPLive editorial team spoke with Brett King, MD, PhD—associate professor of dermatology at the Yale University School of Medicine Department of Dermatology—about his team’s late-breaking data on bempikibart for those with severe alopecia areata.1 The findings from the SIGNAL-AA phase 2a study on bempikibart, a drug formally known as ADX-914, highlight the medication’s efficacy among patients in terms of Severity of...

1 month ago | hcplive.com | Tim Smith |Linda Gold |Arash Mostaghimi |Brett King |Raj Chovatiya

Author(s):,This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting. As the American Academy of Dermatology (AAD) 2025 Annual Meeting is beginning this week, the HCPLive editorial team interviewed 4 leading experts in the field of dermatology to describe the elements of AAD to which they are most looking forward.